Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Correction of NR2E3 Associated Enhanced S-cone Syndrome Patient-specific iPSCs using CRISPR-Cas9.

Bohrer LR, Wiley LA, Burnight ER, Cooke JA, Giacalone JC, Anfinson KR, Andorf JL, Mullins RF, Stone EM, Tucker BA.

Genes (Basel). 2019 Apr 5;10(4). pii: E278. doi: 10.3390/genes10040278.

2.

Feeder-free differentiation of cells exhibiting characteristics of corneal endothelium from human induced pluripotent stem cells.

Wagoner MD, Bohrer LR, Aldrich BT, Greiner MA, Mullins RF, Worthington KS, Tucker BA, Wiley LA.

Biol Open. 2018 May 8;7(5). pii: bio032102. doi: 10.1242/bio.032102.

3.

CRISPR-Cas9 genome engineering: Treating inherited retinal degeneration.

Burnight ER, Giacalone JC, Cooke JA, Thompson JR, Bohrer LR, Chirco KR, Drack AV, Fingert JH, Worthington KS, Wiley LA, Mullins RF, Stone EM, Tucker BA.

Prog Retin Eye Res. 2018 Jul;65:28-49. doi: 10.1016/j.preteyeres.2018.03.003. Epub 2018 Mar 22. Review.

PMID:
29578069
4.

CRISPR-Cas9-Mediated Correction of the 1.02 kb Common Deletion in CLN3 in Induced Pluripotent Stem Cells from Patients with Batten Disease.

Burnight ER, Bohrer LR, Giacalone JC, Klaahsen DL, Daggett HT, East JS, Madumba RA, Worthington KS, Mullins RF, Stone EM, Tucker BA, Wiley LA.

CRISPR J. 2018 Feb;1:75-87. doi: 10.1089/crispr.2017.0015.

5.

LSD1 promotes S-phase entry and tumorigenesis via chromatin co-occupation with E2F1 and selective H3K9 demethylation.

He Y, Zhao Y, Wang L, Bohrer LR, Pan Y, Wang L, Huang H.

Oncogene. 2018 Jan 25;37(4):534-543. doi: 10.1038/onc.2017.353. Epub 2017 Oct 9.

PMID:
28991226
6.

ADAM17 in tumor associated leukocytes regulates inflammatory mediators and promotes mammary tumor formation.

Bohrer LR, Chaffee TS, Chuntova P, Brady NJ, Witschen PM, Kemp SE, Nelson AC, Walcheck B, Schwertfeger KL.

Genes Cancer. 2016 Jul;7(7-8):240-253. doi: 10.18632/genesandcancer.115.

7.

Epiregulin contributes to breast tumorigenesis through regulating matrix metalloproteinase 1 and promoting cell survival.

Farooqui M, Bohrer LR, Brady NJ, Chuntova P, Kemp SE, Wardwell CT, Nelson AC, Schwertfeger KL.

Mol Cancer. 2015 Jul 29;14:138. doi: 10.1186/s12943-015-0408-z.

8.

p300 acetyltransferase regulates androgen receptor degradation and PTEN-deficient prostate tumorigenesis.

Zhong J, Ding L, Bohrer LR, Pan Y, Liu P, Zhang J, Sebo TJ, Karnes RJ, Tindall DJ, van Deursen J, Huang H.

Cancer Res. 2014 Mar 15;74(6):1870-1880. doi: 10.1158/0008-5472.CAN-13-2485. Epub 2014 Jan 30.

9.

Activation of the FGFR-STAT3 pathway in breast cancer cells induces a hyaluronan-rich microenvironment that licenses tumor formation.

Bohrer LR, Chuntova P, Bade LK, Beadnell TC, Leon RP, Brady NJ, Ryu Y, Goldberg JE, Schmechel SC, Koopmeiners JS, McCarthy JB, Schwertfeger KL.

Cancer Res. 2014 Jan 1;74(1):374-86. doi: 10.1158/0008-5472.CAN-13-2469. Epub 2013 Nov 6.

10.

FOXO1 binds to the TAU5 motif and inhibits constitutively active androgen receptor splice variants.

Bohrer LR, Liu P, Zhong J, Pan Y, Angstman J, Brand LJ, Dehm SM, Huang H.

Prostate. 2013 Jul;73(10):1017-27. doi: 10.1002/pros.22649. Epub 2013 Feb 6.

11.

Macrophages promote fibroblast growth factor receptor-driven tumor cell migration and invasion in a CXCR2-dependent manner.

Bohrer LR, Schwertfeger KL.

Mol Cancer Res. 2012 Oct;10(10):1294-305. doi: 10.1158/1541-7786.MCR-12-0275. Epub 2012 Aug 14.

12.

Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2.

Chen S, Bohrer LR, Rai AN, Pan Y, Gan L, Zhou X, Bagchi A, Simon JA, Huang H.

Nat Cell Biol. 2010 Nov;12(11):1108-14. doi: 10.1038/ncb2116. Epub 2010 Oct 10.

13.

Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: a potential mechanism of androgen-refractory progression of prostate cancer.

Bohrer LR, Chen S, Hallstrom TC, Huang H.

Endocrinology. 2010 Nov;151(11):5136-45. doi: 10.1210/en.2010-0436. Epub 2010 Sep 29.

Supplemental Content

Loading ...
Support Center